Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

2 months ago 29

Vandita Jadeja

Tue, July 21, 2026 astatine 10:00 AM CDT 4 min read

Quick Read

JNJ's 64-year dividend streak and oncology momentum marque it the steadier buy, portion ABT's 18x guardant P/E offers a cheaper turnaround entry.
Abbott's involvement disbursal surged from $50 cardinal to $299 cardinal post-acquisition, and Cologuard indispensable present durable borderline enlargement to warrant the indebtedness load.
Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Johnson & Johnson didn't marque the cut. Grab the names FREE today.

Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) some precocious posted net that amusement 2 healthcare giants moving successful other strategical directions.

A bluish humor glucose metre with a greenish and achromatic trial portion inserted, a achromatic lancing device, and a metallic and teal stethoscope are arranged connected a achromatic 'Blood Glucose Testing Record' paper. The aesculapian items are placed connected a airy woody surface.

JNJ is tightening its absorption by spinning disconnected Orthopaedics, portion Abbott conscionable closed a $21 cardinal Exact Sciences deal. The businesses down these tickers look thing alike close now.

Oncology Powers JNJ. Cancer Diagnostics Reshapes Abbott.

JNJ's Q1 study leaned connected its Innovative Medicine engine, with conception gross of $15.43 billion, up 11.2%. DARZALEX brought successful $3.96 cardinal (+22.5%), TREMFYA jumped 68.3%, and CARVYKTI kept scaling. That momentum is doing dense lifting due to the fact that STELARA collapsed 59.7% against biosimilars, a existent resistance that TREMFYA is fortunately absorbing.

Abbott's Q2 communicative is different. Medical Devices delivered $5.85 billion, up 9%, led by FreeStyle Libre continuous glucose monitors astatine $2.19 billion. Diagnostics surged 42.3% astir wholly due to the fact that Cologuard from Exact Sciences contributed $919 million. Strip that retired and comparable income grew a much humble 4.8%, which is little flashy but much representative.

CEO Joaquin Duato framed JNJ's 4th arsenic "a beardown commencement to 2026", citing approvals for ICOTYDE and VARIPULSE Pro. Abbott CEO Robert Ford was much forward-looking, saying results "reflect the momentum we are building" heading into H2.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Johnson & Johnson didn't marque the cut. Grab the names FREE today.

Narrowing the Portfolio vs. Widening the Net

Lens	JNJ	Abbott
Core Bet	Pharma innovation, compartment therapy	Devices, glucose monitoring, crab dx
Recent Strategic Move	Orthopaedics spin-off successful 18 to 24 months	Closed $21B Exact Sciences woody
Key Vulnerability	STELARA biosimilar cliff	Nutrition weakness, CGM contention
Forward P/E	22	18

JNJ is pruning. Abbott is stacking.

JNJ raised full-year gross guidance to $100.3B to $101.3B and adjusted EPS to $11.45 to $11.65. Abbott lifted its EPS scope to $5.45 to $5.60, though acquisition financing pushed involvement disbursal to $299 cardinal from $50 million. Digesting that indebtedness is existent work.

Read Entire Article